Assay or astray? discrepancies in efanesoctocog alfa monitoring
- 1Laboratoire d’Hématologie, Unité Hémostase, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
- 2Centre de Ressource et Compétences des Maladies Hémorragiques Congénitales, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Abstract
Background
Efanesoctocog alfa (EFA) is an ultraextended half-life factor VIII (FVIII) with a unique structure that may influence laboratory monitoring. Although assay discrepancies have been described in spiked samples, data in patient samples are limited.Objectives
To assess the performance of seven FVIII assays for measuring EFA in patient plasma and compare results with those from spiked samples.Methods
FVIII activity was measured using four one-stage assays (OSAs) and three chromogenic assays (CSAs) on two analyzers. Assays were calibrated either with human plasma or an EFA-specific calibrator. Measurements were performed in FVIII-deficient plasma spiked with EFA and in samples from patients with hemophilia A treated with EFA. Results were compared with a reference assay (Actin FSL) and expressed as recovery percentages (acceptable range: 80%-120%).Results
In spiked samples, plasma-calibrated CSA overestimated FVIII activity (+37% to +94%), whereas EFA-calibrated CSA showed good agreement with the reference assay (+2% to +16%). OSA results were generally acceptable, with slight underestimation depending on the reagent. In patient samples, patterns differed markedly: most assays deviated significantly from the reference, and none remained within the acceptable recovery range across the full FVIII spectrum. Compared with spiked samples, discrepancies were more pronounced at later time points and trough levels, where OSA tended to overestimate FVIII activity, whereas EFA-calibrated CSA underestimated activity.Conclusion
Assay performance for EFA differs between spiked and patient samples, underscoring the limitations of in vitro evaluations. No assay provided consistent agreement with the reference assay across the full FVIII range, highlighting the need for cautious interpretation and improved standardization of EFA monitoring in clinical practice.
Related
- Efanesoctocog Alfa for the Management of a Life-Threatening Intracranial Haemorrhage in Mild Haemophilia A: A Case Report.
- Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa
- Restoration of spermatogenesis in a male with prolactinoma-induced hypogonadotropic hypogonadism using follitropin delta and recombinant choriogonadotropin alfa: a case report
- Comparative outcomes of conventional follitropin delta 15 µg/day versus follitropin alfa 225 IU/day for ovarian stimulation: results from an exploratory post hoc analysis of Spanish participants from the ADAPT-1 randomized controlled trial
- 514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC
BibTeX
@article{herb2026assay,
title = {{Assay or astray? discrepancies in efanesoctocog alfa monitoring}},
author = {Agathe Herb and Jordan Wimmer and Sarra Derbal and Manon Dolt and Léa Pierre and Olivier Feugeas and Laurent Mauvieux and Dominique Desprez and Laurent Sattler},
journal = {Research and practice in thrombosis and haemostasis},
year = {2026},
month = oct,
doi = {10.1016/j.rpth.2026.106994},
url = {https://europepmc.org/article/PMC/PMC13717027},
note = {CC BY},
}
RIS
TY - JOUR
TI - Assay or astray? discrepancies in efanesoctocog alfa monitoring
AU - Agathe Herb
AU - Jordan Wimmer
AU - Sarra Derbal
AU - Manon Dolt
AU - Léa Pierre
AU - Olivier Feugeas
AU - Laurent Mauvieux
AU - Dominique Desprez
AU - Laurent Sattler
PY - 2026
DA - 2026/10/01
JO - Research and practice in thrombosis and haemostasis
DO - 10.1016/j.rpth.2026.106994
UR - https://europepmc.org/article/PMC/PMC13717027
AB - Background Efanesoctocog alfa (EFA) is an ultraextended half-life factor VIII (FVIII) with a unique structure that may influence laboratory monitoring. Although assay discrepancies have been described in spiked samples, data in patient samples are limited.Objectives To assess the performance of seven FVIII assays for measuring EFA in patient plasma and compare results with those from spiked samples.Methods FVIII activity was measured using four one-stage assays (OSAs) and three chromogenic assays (CSAs) on two analyzers. Assays were calibrated either with human plasma or an EFA-specific calibrator. Measurements were performed in FVIII-deficient plasma spiked with EFA and in samples from patients with hemophilia A treated with EFA. Results were compared with a reference assay (Actin FSL) and expressed as recovery percentages (acceptable range: 80%-120%).Results In spiked samples, plasma-calibrated CSA overestimated FVIII activity (+37% to +94%), whereas EFA-calibrated CSA showed good agreement with the reference assay (+2% to +16%). OSA results were generally acceptable, with slight underestimation depending on the reagent. In patient samples, patterns differed markedly: most assays deviated significantly from the reference, and none remained within the acceptable recovery range across the full FVIII spectrum. Compared with spiked samples, discrepancies were more pronounced at later time points and trough levels, where OSA tended to overestimate FVIII activity, whereas EFA-calibrated CSA underestimated activity.Conclusion Assay performance for EFA differs between spiked and patient samples, underscoring the limitations of in vitro evaluations. No assay provided consistent agreement with the reference assay across the full FVIII range, highlighting the need for cautious interpretation and improved standardization of EFA monitoring in clinical practice.
SN - 2475-0379
ER -